

COVID 19



Keeping Up with a Moving Target



CME Information

Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	JNJ: Ownership equity Scientific Consulting: Verily, EMD Serono, Shionogi DMSB: Humanigen

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including monoclonal antibodies, antivirals, and several vaccine platforms.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.



CME Information

To attest for CME/CE/AAPA credit, please visit
COVID19.dkbmed.com



Learning Objectives

- Discuss new FDA authorization for second booster doses



Thank You

This activity is supported by an educational grant from Gilead Sciences, Inc. and in-kind support by DKBmed LLC

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters.

Please see **COVID19.DKBmed.com** for additional resources and educational activities



Paul Auwaerter, MD, MBA, FIDSA


Clinical Director, Division of Infectious Diseases

Sherrilyn and Ken Fisher Professor of Medicine

Fisher Center for Environmental Infectious Diseases

Johns Hopkins University School of Medicine

BA.2 Lineage Subvariant Now the Dominant New Infection in the US



<https://covid.cdc.gov/covid-data-tracker/#variant-proportions> (3/29)

Where Does BA.2 Fall?




FIGURE 1. Venn diagram illustrating the wealth of shared and differing mutations in the Omicron ... [+] CREDIT: ACCESS HEALTH INTERNATIONAL

Bill Haseltine, Forbes 2022

In Vitro Therapeutic Activity



The Question Most Everyone Asks...BOOSTERS

FDA authorizes second coronavirus booster shot for people 50 and older

By Carolyn Y. Johnson and Lena H. Sun

Today at 10:35 a.m. EDT | Updated today at 2:45 p.m. EDT

 Listen to article 8 min



The decision to offer a fourth vaccine dose in the United States drew heavily from data in Israel, which approved in January a fourth dose for people most vulnerable to covid-19. (Maya Alleruzzo/AP)



MOST READ HEALTH >



1 CDC: If you got J&J's vaccine and booster, consider an mRNA shot now

2 Clinics, hospitals brace for end of cushion for uninsured covid care



3 Staying safe with frozen fruits and veggies



4 What to know about the omicron variant and subvariant BA.2



Booster #2: Dose #4 or #5

Who:

- All > 50 yrs (**dose #4**)
 - At least 4 months after first booster (dose #3)
- Solid organ transplants or similar immune risk (**dose #5**)
 - At least 4 months after booster #1 (dose #4)

Risks differ among groups above

- Age, co-morbidities, timing of last shot, circulating variant, & rates
- Debate about benefits

CDC/ACIP expected to say “may” for the > 50 yrs group

Data on Fourth Dose from Israel

Dose #4 mRNA vaccine

- Safe, immunogenic
- Raises vaccine efficacy somewhat
- Dose #3 appears to have peak humoral response
- Marginal benefit efficacy in HCWs who remain with high VL due to Omicron

Case-match control study 4 v. 3 dose mRNA with 10 wk follow-up

- Age > 60 yrs, protection against severe COVID compared to 3 dose
- Peak protection 3 wks after dose #4, wanes faster than dose #3



For the newly authorized second booster, is there any advantage to using vaccine that was not part of primary series or first booster?



The CDC statement on isolation states that people who test positive for COVID-19 should isolate for five days. Is five days enough, considering that many people still test positive on rapid antigen for around 10 days?



Thank You!

To receive CME/CE/AAPA credit:

Complete the evaluation on at COVID19.DKBmed.com

Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

- Access our resource hub at COVID19.DKBmed.com

To ask your own question, email:

- QA@dkbmed.com